Functional symptoms in clinically definite MS--pseudo-relapse syndrome.
Affiliation
Department of Clinical Neurology, Cork University Hospital, Wilton, Cork,, Ireland. ainemerwick@yahoo.co.ukIssue Date
2012-02-03T15:04:43ZMeSH
AdultFemale
Humans
Male
Middle Aged
Multiple Sclerosis, Relapsing-Remitting/complications/*diagnosis/psychology
Psychophysiologic Disorders/diagnosis/etiology/therapy
Syndrome
Metadata
Show full item recordCitation
Int MS J. 2008 Jun;15(2):47-51.Journal
International MS journal / MS ForumPubMed ID
18782499Abstract
Although the diagnostic criteria for multiple sclerosis (MS) have become more formalized and sensitive in the era of magnetic resonance imaging (MRI) scanning, the assessment of individual relapses may not always be straightforward or easily linked to a particular lesion seen on imaging. In addition, acute episodes often have to be assessed outside of normal working hours or when the individual patients usual medical team is not available. Often the emergency department physicians have little formal neurological training and are under time pressure to get patients through the system as quickly as possible. It is therefore possible to mislabel functional symptoms as being true relapses. To illustrate scenarios of possible pseudo-relapse, three clinical vignettes are described. Misclassification of functional symptoms as relapse carries a number of inherent risks. Functional symptoms can be multifactorial and may cause a burden of disease. A multidisciplinary approach may be useful in minimizing unnecessary harm and identify if there is more than meets the eye to an episode of clinical deterioration.Language
engISSN
1352-8963 (Print)1352-8963 (Linking)
Collections
Related articles
- Determinants of disability in multiple sclerosis at various disease stages: a multiparametric magnetic resonance study.
- Authors: Pulizzi A, Rovaris M, Judica E, Sormani MP, Martinelli V, Comi G, Filippi M
- Issue date: 2007 Aug
- Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
- Authors: Patti F, Amato MP, Trojano M, Bastianello S, Tola MR, Goretti B, Caniatti L, Di Monte E, Ferrazza P, Brescia Morra V, Lo Fermo S, Picconi O, Luccichenti G, COGIMUS Study Group
- Issue date: 2009 Jul
- Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial.
- Authors: Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, Elovaara I, Fazekas F, Hartung HP, Hillert J, King J, Komoly S, Lubetzki C, Montalban X, Myhr KM, Ravnborg M, Rieckmann P, Wynn D, Young C, Filippi M, PreCISe study group
- Issue date: 2009 Oct 31
- MRI as an outcome in multiple sclerosis clinical trials.
- Authors: Daumer M, Neuhaus A, Morrissey S, Hintzen R, Ebers GC
- Issue date: 2009 Feb 24
- Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis.
- Authors: Sormani MP, Stubinski B, Cornelisse P, Rocak S, Li D, De Stefano N
- Issue date: 2011 May